UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
IDAP medtech innovation pathway set for launch in 2023
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.
You may also be interested in...
The number of UK approved bodies designated to issue UKCA marking leapt from four to seven in August, adding much-needed file auditing capacity to Great Britain’s evolving medtech regulatory system. Next up: the MHRA’s consultation on accepting overseas-approved products onto the market.
The pace of activity in medtech circles as the UK government and MHRA target a robust-but-agile regulatory system for Great Britain has been fairly relentless. Manufacturers serving the British medtech markets eye the plans and promises with patience – for now at least.
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.